Terns Pharmaceuticals (TERN) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Terns Pharmaceuticals (NASDAQ: TERN):

• 12/22/2025 – Terns Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Terns Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/11/2025 – Terns Pharmaceuticals had its price target raised by analysts at Citizens Jmp from $35.00 to $57.00. They now have a “market outperform” rating on the stock.
• 12/10/2025 – Terns Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $70.00 price target on the stock.
• 12/9/2025 – Terns Pharmaceuticals had its price target raised by analysts at Oppenheimer Holdings, Inc. from $28.00 to $58.00. They now have an “outperform” rating on the stock.
• 12/9/2025 – Terns Pharmaceuticals had its price target raised by analysts at BMO Capital Markets from $35.00 to $54.00. They now have an “outperform” rating on the stock.
• 12/9/2025 – Terns Pharmaceuticals had its price target raised by analysts at Truist Financial Corporation from $35.00 to $56.00. They now have a “buy” rating on the stock.
• 12/9/2025 – Terns Pharmaceuticals had its price target raised by analysts at Mizuho from $33.00 to $54.00. They now have an “outperform” rating on the stock.
• 12/9/2025 – Terns Pharmaceuticals had its price target raised by analysts at HC Wainwright from $20.00 to $60.00. They now have a “buy” rating on the stock.
• 12/9/2025 – Terns Pharmaceuticals had its price target raised by analysts at Barclays PLC from $36.00 to $56.00. They now have an “overweight” rating on the stock.
• 12/8/2025 – Terns Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/4/2025 – Terns Pharmaceuticals was upgraded by analysts at UBS Group AG to a “strong-buy” rating.
• 12/1/2025 – Terns Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/28/2025 – Terns Pharmaceuticals was given a new $33.00 price target on by analysts at Mizuho.
• 11/26/2025 – Terns Pharmaceuticals was given a new $35.00 price target on by analysts at JMP Securities.
• 11/26/2025 – Terns Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 11/26/2025 – Terns Pharmaceuticals had its price target raised by analysts at Citizens Jmp from $25.00 to $35.00. They now have a “market outperform” rating on the stock.
• 11/25/2025 – Terns Pharmaceuticals had its price target raised by analysts at Barclays PLC from $28.00 to $36.00. They now have an “overweight” rating on the stock.
• 11/24/2025 – Terns Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Terns Pharmaceuticals had its price target raised by analysts at Truist Financial Corporation from $28.00 to $35.00. They now have a “buy” rating on the stock.
• 11/18/2025 – Terns Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/18/2025 – Terns Pharmaceuticals had its price target raised by analysts at BMO Capital Markets from $22.00 to $30.00. They now have an “outperform” rating on the stock.
• 11/13/2025 – Terns Pharmaceuticals had its price target raised by analysts at Mizuho from $32.00 to $33.00. They now have an “outperform” rating on the stock.
• 11/11/2025 – Terns Pharmaceuticals had its price target raised by analysts at Barclays PLC from $27.00 to $28.00. They now have an “overweight” rating on the stock.
• 11/4/2025 – Terns Pharmaceuticals had its “buy” rating reaffirmed by analysts at Truist Financial Corporation. They now have a $28.00 price target on the stock, up previously from $20.00.
• 11/4/2025 – Terns Pharmaceuticals had its price target raised by analysts at Barclays PLC from $14.00 to $27.00. They now have an “overweight” rating on the stock.
• 11/4/2025 – Terns Pharmaceuticals had its price target raised by analysts at Mizuho from $9.00 to $32.00. They now have an “outperform” rating on the stock.
• 11/4/2025 – Terns Pharmaceuticals was upgraded by analysts at HC Wainwright from a “neutral” rating to a “buy” rating. They now have a $20.00 price target on the stock.
• 11/3/2025 – Terns Pharmaceuticals had its price target raised by analysts at BMO Capital Markets from $15.00 to $22.00. They now have an “outperform” rating on the stock.
• 11/3/2025 – Terns Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $24.00 price target on the stock.
• 11/3/2025 – Terns Pharmaceuticals had its price target raised by analysts at Jefferies Financial Group Inc. from $28.00 to $35.00. They now have a “buy” rating on the stock.
• 11/3/2025 – Terns Pharmaceuticals was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating.

Insiders Place Their Bets

In related news, Director Jill M. Quigley sold 24,520 shares of the business’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $18.00, for a total value of $441,360.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 1.50% of the company’s stock.

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.